Summary Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m2 iv.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-') starting on al., 1984; Dhingra et al., 1985; Kawahara et al., 1991). Treatment regimens in which one further active chemotherapeutic agent has been added to vinca alkaloid and cisplatin have been tried in an attempt to improve response and survival rates. The combination of mitomycin with VP (MVP) has been reported to achieve response rates of 20-61% (Kris et al., 1986; Einhorn et al., 1986; Miller et al., 1986; Joss et al., 1990; Fukuoka et al., 1991) . Although these intensive combination chemotherapy regimens achieve an improvement in objective response, serious drug-related toxicity is often experienced. Active chemotherapeutic regimens that are less toxic would therefore be desirable.
The use of drug combinations in the treatment of advanced non-small-cell lung cancer (NSCLC) has been intensively investigated. Their use, however, remains controversial.
Cisplatin (CDDP) in combination with vinca alkaloids, vindesine (VDS) or vinblastine (VBL), has been widely used for induction treatment of NSCLC since Gralla et al. (1981) first demonstrated a response rate of 43%. Response rates of approximately 30% have since been shown in advanced NSCLC using a combination of VDS + CDDP (VP) (Elliott et al., 1984; Dhingra et al., 1985; Kawahara et al., 1991) . Treatment regimens in which one further active chemotherapeutic agent has been added to vinca alkaloid and cisplatin have been tried in an attempt to improve response and survival rates. The combination of mitomycin with VP (MVP) has been reported to achieve response rates of 20-61% (Kris et al., 1986; Einhorn et al., 1986; Miller et al., 1986; Joss et al., 1990; Fukuoka et al., 1991) . Although these intensive combination chemotherapy regimens achieve an improvement in objective response, serious drug-related toxicity is often experienced. Active chemotherapeutic regimens that are less toxic would therefore be desirable.
Although 5-fluorouracil (5-FU) shows limited activity as a single agent in NSCLC, it reacts synergistically with CDDP against murine tumours (Schabel et al., 1979; Mabel and Little, 1979) . This has prompted clinical studies of the combination of CDDP and 5-FU against NSCLC. Weiden et al. (1985) have reported a response rate of 37% in NSCLC using this combination. Continuous infusion (CI) of 5-FU has been found to increase the therapeutic response and decrease myelosuppression compared with the use of bolus injections (Seifert et al., 1975; Kish et al., 1985) . Decker et al. (1983) found the combination of CDDP and a 5 day infusion of 5-FU useful in the treatment of head and neck cancers. They reported a 94% response rate, including a complete response rate of 63%. In a pilot study by the Mid-Atlantic Oncology Program, CDDP (120 mg m-2) infused over 24 h + CI 5-FU gave a response rate of 47% in advanced NSCLC (Heim et al., 1986) . Toxicology profiles of these CDDP + 5-FU regimens indicate less haematological and nephrological toxicity than standard dose VP and MVP regimens. However, a higher incidence of severe mucositis was observed, and, if doxorubicin was also included, clinically significant myelosuppression, similar to that encountered with VP and MVP regimens, was also experienced (Ruckdeschel et al., 1981) . Although improved response rates have been achieved, an optimum dose and schedule has yet to be identified.
These reports encouraged us to perform a phase II trial of CDDP and VDS in combination with CI 5-FU against advanced NSCLC. We decided to administer VP separately from CI 5-FU, in an attempt to minimise toxicity without affecting efficacy. In most of the earlier studies CDDP and 5-FU were administered on the same day. The trial was designed so that CDDP + VDS and CI 5-FU were injected on alternate weeks. The immediate objectives were to determine the major objective response rate to this treatment programme, and to define the toxicities involved. The activity of this combination against advanced NSCLC has not been studied previously. (Mountain, 1986) . The severity of drug toxicity was graded according to the WHO toxicity scales (Miller et al., 1981) .
Drug administration
The treatment scheme is summarised in Figure 1 .
The chemotherapy was given intravenously as follows: CDDP (60 mg m-2) in 500 ml of normal saline over 1 h + VDS (3 mg m-2) by bolus injection on day 1; and 5-FU (800 mg m-2 day-') by continuous 3 day infusion into a peripheral vein starting on day 8 (PVF). This treatment was repeated every 14 days for at least three cycles, so that CDDP and VDS alternated weekly with a 3 day continuous infusion of 5-FU. A 25% reduction in drug dosage was required in subsequent cycles for those patients who experienced WHO grade 4 myelotoxicity, grade 2 nephrotoxicity, and/or another severe treatment-related toxicity. For patients who achieved a response, the treatment was continued for an additional three cycles. All patients received at least 2.5 1 of hydration on the day of CDDP administration with forced diuresis. Treatment then continued until tumour progression was observed, or until no further response was achieved over three successive cycles.
Concomitant radiation therapy to the brain and bone was permitted. Granulocyte colony-stimulating factor (G-CSF) and other cytokines were not used in this study. Antiemetic therapy, using methylprednisolone and metoclopramide, was given at the discretion of the investigator.
Response criteria Patients were evaluated for response after three treatment cycles. A complete response (CR) was defined as complete disappearance of all measurable disease for at least 4 weeks without appearance of any new lesions. A partial response (PR) was defined as a 50% or more reduction in the sum of the products of the two longest perpendicular diameters of measurable lesions for a least 4 weeks; no change (NC) was defined as a reduction of less than 50% to an increase of less than 25% in measurable disease, without the appearance of new lesions. Progressive disease (PD) was defined as an increase of more than 25% in the size of any measurable lesion, or the appearance of new lesions.
Survival was calculated from the start of treatment to death or the date of the last follow-up, using the actuarial method of Kaplan-Meier. The exact confidence intervals for the response rates were calculated according to the formula proposed by Ghosh (1979 (74%) and grade 3 or 4 in four patients (9%). Non-haematological toxicity was generally mild: 21 patients (45%) suffered vomiting, but this never exceeded grade 2; grade 1 diarrhoea was observed in seven patients (15%); and peripheral neuropathy in nine patients (19%). A transient rise in serum creatinine levels (>2.0 mg ml-') occurred in two patients (4%), and elevation of sGOT and/or sGPT (> 100 U L-l) in one patient (2%), none of whom required specific therapy. No stomatitis was observed. Phlebitis at the site of drug administration was noted in 24 patients (51%); all of these improved under conservative management. Pigmentation of the overlying skin was seen in 18 (38%) patients. Grade 1 alopecia was seen in 16 patients (34%) and grade 2 in 12 patients (26%).
Discussion
The observed response rate of 40.4% with a median survival of 41.6 weeks for patients with advanced NSCLC receiving PVF therapy is similar to that recently reported with several T Nakano et i x 1099
investigators (Fukuoka et al., 1991 (Fukuoka et al., , 1992 for the MVP regimen using CDDP in moderate doses (80 mg m-3). (Fukuoka et al., 1992) . The combination of CDDP + 5-FU has been most effective against squamous cell lung cancer (Weiden et al., 1985) , and squamous cell head and neck cancer (Decker et al., 1983) . Klastersky et al. (1990) have demonstrated that squamous cell carcinoma is associated with a significantly higher response rate than adenocarcinoma in a randomised study comparing CDDP or carboplatin with etoposide in patients with NSCLC. We achieved a better response rate im squamous cell carcinoma (56.3%) than in non-squamous cell carcinoma (32.3%), using our PVF therapy.
Fukuoka et al. (1992) reviewed the results of MVP therapy for advanced NSCLC, and showed that MVP regimens using moderate-or high-dose CDDP (75-120 mg m-2) achieved a response rate of 49%, whereas the rate was 30% for low-dose CDDP (60 mg m-' or less). They concluded that CDDP should be given at a dose of 75 mg m-2 or more. To maximise chemotherapeutic activity against NSCLC, many investigators are seeking maximal dose intensity for the drug combinations. However, this strategy is often associated with severe toxicity. Weekly administration and an intravenous CI schedule for several agents may improve efficacy and decrease toxicity, compared with the use of conventional i.v. bolus injections (Jacobs et al., 1978; Carlson and Sikic, 1983; Vogelzang, 1984; Saito et al., 1990; Miles et al., 1991) . For some drugs, conventional intermittent scheduling every 3-4 weeks may be inferior to alternative means of drug delivery (O'Dwyer and Comis, 1989) . In a randomised trial comparing CDDP + CI 5-FU with CDDP + bolus injections of 5-FU, the latter treatment schedule was clearly inferior in terms of the response achieved (Kish et al., 1985) . The major advantage of using a CI delivery of 5-FU instead of bolus injection is a marked reduction in bone marrow toxicity (Sikic, 1986) . In 1991, the Cancer and Leukaemia Group B reported the result of a random study comparing CDDP + CI 5-FU with CDDP + CI 5-FU + VBL for NSCLC, which showed that neither regimen was effective, and that toxicities were more frequent and more severe in the latter (Richards et al., 1991) . However, their treatment was administered using a standard intermittent schedule every 4 weeks.
To minimise toxicity, we separated the administration of CDDP + VDS and CI 5-FU in the treatment schedule, so that CDDP + VDS and a 3 day CI 5-FU were given on alternate weeks. Although this PVF schedule employed a low dose of CDDP (60 mg m-2), the response rate was better than that to CDDP (100 mg m-2) + CI 5-FU (Weiden et al., 1985) , or to a 24 h infusion of CDDP (100 mg m-2) + CI 5-FU + etoposide (Rosenthal et al., 1992) . Furthermore, our results were similar to those observed using a weekly schedule of CDDP and CI 5-FU + VBL, and to those using CI CDDP + 5-FU + bolus methotrexate (Lynch et al., 1992) .
The toxicity profile for the weekly CDDP-based regimen used in the Southwest Oncology Group Study was similar to the standard-dose regimen (Higano et al., 1991) . The most active VP and MVP regimens for advanced NSCLC also cause moderate or severe myelosuppression (Luedke et al., 1990; Fukuoka et al., 1992) . However, the incidence of severe haematotoxicity was low and well tolerated using our PVF regimen. Vomiting was experienced by most patients, but never exceeded grade 2 and could easily be controlled with antiemetics. The development of chemical phlebitis at the infusion site occurred in 51% of the patients, which sometimes necessitated the replacement of the peripheral venous catheter. Phlebitis has been reported in 45% of patients treated with CDDP + CI 5-FU (Verweij et al.. 1989) . A high n'sk of cardiovascular toxicity has also been reported for 5-FU (Pottage et al., 1978; Labianca et al.. 1982 ), but we observed no such side-effect.
There were two deaths from other diseases during our study. One hypertensive patient, whose WBC and thrombocyte count were normal, died of a cerebral haemorrhage. The other died of a diabetic complication, but without any indication of the haematological or non-haematological events associated with the drugs administered. These deaths cannot therefore be attributed to drug-related toxicity.
In conclusion, this PVF regimen for the treatment of advanced NSCLC achieved a response rate similar to other active combination regimens, and was less toxic. STEPHENS D AND HUI S. (1986) . Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin mitomycin C in advanced non-small-cell lung cancer. J. Clin. Oncol., 4, 1037-1043. ELLIOTT 
